Ramesh K Ramanathan1, Gary W Thomas2, Alok A Khorana3, Satish Shah4, Cathy Zhou5, Sofia Wong5, George Cole6, Danelle James5, Nashat Y Gabrail7. 1. Honor Health Research Institute/Translational Genomics Research Institute, Scottsdale, Arizona, USA. 2. South Carolina Cancer Specialists, Hilton Head Island, South Carolina, USA. 3. University of Rochester, Rochester, New York, USA. 4. Gettysburg Cancer Center, Gettysburg, Pennsylvania, USA. 5. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA. 6. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, USA, gecole@pcyc.com. 7. Gabrail Cancer Center, Canton, Ohio, USA.
Abstract
OBJECTIVES: Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promoting cell migration and angiogenesis. The study objective was to evaluate safety, pharmacokinetics, and efficacy of PCI-27483, a selective FVIIa inhibitor. METHODS: This was an open-label, multicenter phase 2 trial of patients with advanced pancreatic cancer. Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483-gemcitabine versus gemcitabine alone. RESULTS: Target international normalized ratio (between 2.0-3.0) was achieved following PCI-27483 treatment. Overall safety of PCI-27483-gemcitabine (n = 26) was similar to gemcitabine alone (n = 16), with a higher incidence of mostly low-grade bleeding events (65% vs. 19%). Progression-free survival (PFS) and overall survival (OS) were not significantly different between patients treated with PCI-27483-gemcitabine (PFS: 3.7 months, OS: 5.7 months) and those treated with gemcitabine alone (PFS: 1.9 months, OS: 5.6 months). CONCLUSIONS: Targeted inhibition of the coagulation cascade was achieved by administering PCI-27483. PCI-27483-gemcitabine was well tolerated, but superiority to single agent gemcitabine was not demonstrated. The Author(s). Published by S. Karger AG, Basel.
RCT Entities:
OBJECTIVES:Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promoting cell migration and angiogenesis. The study objective was to evaluate safety, pharmacokinetics, and efficacy of PCI-27483, a selective FVIIa inhibitor. METHODS: This was an open-label, multicenter phase 2 trial of patients with advanced pancreatic cancer. Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483-gemcitabine versus gemcitabine alone. RESULTS: Target international normalized ratio (between 2.0-3.0) was achieved following PCI-27483 treatment. Overall safety of PCI-27483-gemcitabine (n = 26) was similar to gemcitabine alone (n = 16), with a higher incidence of mostly low-grade bleeding events (65% vs. 19%). Progression-free survival (PFS) and overall survival (OS) were not significantly different between patients treated with PCI-27483-gemcitabine (PFS: 3.7 months, OS: 5.7 months) and those treated with gemcitabine alone (PFS: 1.9 months, OS: 5.6 months). CONCLUSIONS: Targeted inhibition of the coagulation cascade was achieved by administering PCI-27483. PCI-27483-gemcitabine was well tolerated, but superiority to single agent gemcitabine was not demonstrated. The Author(s). Published by S. Karger AG, Basel.
Entities:
Keywords:
Anti-tumor; Cancer antigen 19-9; Gemcitabine; Pancreatic cancer; Pancreatic carcinoma; Phase II study; Survival
Authors: A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas Journal: Eur J Cancer Date: 2011-11-17 Impact factor: 9.162
Authors: Gertrud M Hjortoe; Lars C Petersen; Tatjana Albrektsen; Brit B Sorensen; Peder L Norby; Samir K Mandal; Usha R Pendurthi; L Vijaya Mohan Rao Journal: Blood Date: 2004-01-08 Impact factor: 22.113
Authors: Alok A Khorana; Steven A Ahrendt; Charlotte K Ryan; Charles W Francis; Ralph H Hruban; Ying Chuan Hu; Galen Hostetter; Jennifer Harvey; Mark B Taubman Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Jonathan H Shrimp; John Janiszewski; Catherine Z Chen; Miao Xu; Kelli M Wilson; Stephen C Kales; Philip E Sanderson; Paul Shinn; Rick Schneider; Zina Itkin; Hui Guo; Min Shen; Carleen Klumpp-Thomas; Samuel G Michael; Wei Zheng; Anton Simeonov; Matthew D Hall Journal: ACS Infect Dis Date: 2022-06-01 Impact factor: 5.578
Authors: Jonathan H Shrimp; John Janiszewski; Catherine Z Chen; Miao Xu; Kelli M Wilson; Stephen C Kales; Philip E Sanderson; Paul Shinn; Zina Itkin; Hui Guo; Min Shen; Carleen Klumpp-Thomas; Samuel G Michael; Wei Zheng; Anton Simeonov; Matthew D Hall Journal: bioRxiv Date: 2022-02-07
Authors: Dominique Farge; Barbara Bournet; Thierry Conroy; Eric Vicaut; Janusz Rak; George Zogoulous; Jefferey Barkun; Mehdi Ouaissi; Louis Buscail; Corinne Frere Journal: Cancers (Basel) Date: 2020-03-06 Impact factor: 6.639